Trial · NCT07903948
Acceptability of MBSR for People With HS
NCT07903948, Not applicable, Active not recruiting, University of California, San Francisco
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acceptability of MBSR for People With HS. Trials, record NCT07903948. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903948
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acceptability of MBSR for People With HS
- NCT number
- NCT07903948
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 17 participants, actual
- Lead sponsor
- University of California, San Francisco
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Mindfulness-Based Stress Reduction
- First posted
- 2026-10-29
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Acceptability of MBSR for Individuals with HS as Assessed by the Acceptability of Intervention Measure (AIM) | 8 weeks | This tool measures the acceptability of a given intervention. Questions range from 1 to 4. The total score range is 4 to 20. Higher scores indicate greater acceptability of the intervention. |
| Primary | Acceptability of MBSR for Individuals with HS as Assessed by the Theoretical Framework of Acceptability (TFA) | 8 weeks | This tool measures the acceptability of a given intervention and has been adapted to fit the needs of our HS study. This tool has 7 Constructs + 1 General Acceptability Construct, however we did not include the Ethical construct due ambiguity regarding the applicability of the construct to the study (i.e., 6 Constructs + 1 General Acceptability Construct). Questions range from 1 and 5. The total mean score range for our adapted TFA is 6 to 30, and for the General acceptability item is 1 to 5. Higher scores indicate greater acceptability of the intervention. |
| Secondary | Intervention Adherence as Assessed by MBSR Course Attendance | 8 weeks | Intervention adherence will be measured by the percentage of participants who attended at least six of the eight group sessions. |
| Secondary | Study Retention as Assessed by the Percent of Participants who Complete the Study | 8 weeks | Study retention will be measured by the number of participants who completed survey assessments at the 8-week follow-up time-point divided by the number of participants who enrolled in the study, multiplied by 100. |
| Secondary | Feasibility of MBSR for Individuals with HS as Assessed by the Feasibility of Intervention Measure (FIM) | 8 weeks | This tool measures the feasibility of a given intervention. Questions range from 1 to 4. The total score range is 4 to 20. Higher scores indicate greater feasibility of the intervention. |
| Other | Pain Visual Analog Scale | Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks | A simple, one-dimensional measurement tool used to rate the intensity of a patient's pain. Range is 0 to 10. Higher scores indicate greater pain. The reported outcome is the change in Visual Analog Scale score from baseline to 8 weeks. |
| Other | Brief-COPE (Coping Orientation to Problems Experienced) | Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks | This questionnaire is designed to measure the effective and ineffective methods the respondent uses to cope with stressors. Questions range from 1 to 4. The total score range is 28 to 112. There are three overarching sub-scales: * The Problem-Focused Coping range is 8 to 32. * The Emotion-Focused Coping range is 12 to 48. * The Avoidant Coping range is 8 to 32. Higher scores in each sub-scale indicate greater extent of using those methods to cope with stressors. The reported outcome is the change in Brief-COPE sub-scale score from baseline to 8 weeks. |
| Other | Perceived Stress Scale | Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks | This questionnaire measures the degree to which situations in one's life are appraised as stressful. Questions range from 0 to 4. The total score range is 0 to 40. Higher scores indicate higher perceived stress. The reported outcome is the change in Perceived Stress Scale scores from baseline to 8 weeks. |
| Other | Five Facet Mindfulness Questionnaire - Short Form | Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks | The 5 facets are Observing, Describing, Detaching, Acting mindfully, and Loving yourself. Each individual facet is given a score from summing up questions related to that facet. This gives insight into the patient's mindfulness in the past month. Questions range from 1 to 5. Higher scores indicate more frequent actions relating to the facet title. For example, a higher score in "Observing" translates to the respondent being more observant and paying attention to their surroundings. The reported outcome is the change in Five Facet Mindfulness Questionnaire scores from baseline to 8 weeks. |
| Other | Dermatology Life Quality Index | Change From Baseline to 8 Weeks, Change From Baseline to 12 Weeks, Change From Baseline to 20 Weeks | The DLQI is designed for use in patients over the age of 16 and provides insight into how the respondent's skin condition(s) has affected their life over the last week. Questions range from 0 to 3. The total score range is 0 to 30. Higher scores indicate a greater effect the skin condition(s) has on the respondent's life. The reported outcome is the change in Dermatology Life Quality Index scores from baseline to 8 weeks. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903948
GET https://conductscience.org/api/trials/v1/NCT07903948/registered